Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

被引：90

作者：

Pavan, A. ^{[1
,2
]}

Attili, I ^{[1
,2
]}

Pasello, G. ^{[1
]}

Guarneri, V ^{[1
,2
]}

Conte, P. F. ^{[1
,2
]}

Bonanno, L. ^{[1
]}

机构：

[1] Ist Oncol Veneto IOV IRCCS, Med Oncol 2, Via Gattamelata 64, I-35100 Padua, Italy

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷 / 01期

关键词：

Small cell lung cancer; Immune checkpoint inhibitors; Immunotherapy; Tumor microenvironment; Combination therapy; Enhancer of zeste homolog 2; TUMOR-INFILTRATING LYMPHOCYTES; PHASE-III TRIAL; MULTICENTER PHASE-2; PROGNOSTIC-FACTORS; PD-L1; EXPRESSION; 1ST-LINE THERAPY; REGULATORY T; COMBINATION; SURVIVAL; IPILIMUMAB;

D O I：

10.1186/s40425-019-0690-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Management of small cell lung cancer (SCLC) has not changed over the last decades. In more recent years, alterations of DNA repair machinery and other molecular pathways have been identified in SCLC and preclinical data suggest that dysregulation of these pathways might offer new therapeutic opportunities. While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical outcome of several solid tumors, including non-small cell lung cancer, the potential role of ICIs is currently under investigation in SCLC and some promising data are available. However, several clinical and biological hurdles have to be overcome and predictive markers are still eagerly needed. Knowledge of molecular pathways specifically involved in SCLC growth and treatment resistance is essential for a more rational planning of new combinations including ICIs. The present manuscript summarizes the current clinical evidence on immunotherapy in SCLC, describes the molecular bases underlying treatment resistance and discusses the potentialities and the rationale of different therapeutic combinations.

引用

页数：13

共 86 条

[1] Mutational signatures associated with tobacco smoking in human cancer [J].

Alexandrov, Ludmil B. ;

Ju, Young Seok ;

Haase, Kerstin ;

Van Loo, Peter ;

Martincorena, Inigo ;

Nik-Zainal, Serena ;

Totoki, Yasushi ;

Fujimoto, Akihiro ;

Nakagawa, Hidewaki ;

Shibata, Tatsuhiro ;

Campbell, Peter J. ;

Vineis, Paolo ;

Phillips, David H. ;

Stratton, Michael R. .

SCIENCE, 2016, 354 (6312) :618-622

[2] MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study [J].

Alves, Rita de Cassia S. ;

Meurer, Rosalva Thereza ;

Roehe, Adriana Vial .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (12) :2021-2025

[3]

[Anonymous], CANC TREATM SURV FAC

[4]

[Anonymous], 2018, ANN ONCOL S10

[5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[6] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[7] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[8] Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC [J].

Arriola, Edurne ;

Wheater, Matthew ;

Galea, Ian ;

Cross, Nadia ;

Maishman, Tom ;

Hamid, Debbie ;

Stanton, Louise ;

Cave, Judith ;

Geldart, Tom ;

Mulatero, Clive ;

Potter, Vannessa ;

Danson, Sarah ;

Woll, Pennella J. ;

Griffiths, Richard ;

Nolan, Luke ;

Ottensmeier, Christian .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (09) :1511-1521

[9] A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors [J].

Atrafi, Florence ;

Groen, Harry J. M. ;

Byers, Lauren A. ;

Garralda, Elena ;

Lolkema, Martijn P. ;

Sangha, Randeep S. ;

Viteri, Santiago ;

Chae, Young Kwang ;

Camidge, D. Ross ;

Gabrail, Nashat Y. ;

Hu, Beibei ;

Tian, Tian ;

Nuthalapati, Silpa ;

Hoening, Elizabeth ;

He, Lei ;

Komarnitsky, Philip ;

Calles, Antonio .

CLINICAL CANCER RESEARCH, 2019, 25 (02) :496-505

[10] STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer [J].

Attili, Ilaria ;

Karachaliou, Niki ;

Bonanno, Laura ;

Berenguer, Jordi ;

Bracht, Jillian ;

Codony-Servat, Jordi ;

Codony-Servat, Carles ;

Ito, Masaoki ;

Rosell, Rafael .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

← 1 2 3 4 5 6 7 8 9 →